Neratinib Improves Invasive Disease–Free Survival in HER2-Positive Breast Cancer

In the phase III ExteNET trial researchers found that one year of treatment with the HER1, HER2, and HER4 tyrosine kinase inhibitor neratinib improved invasive disease–free survival vs placebo after trastuzumab (Herceptin)-based adjuvant therapy in patients with early-stage HER2-positive breast cancer.

 The Lancet Oncology

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.